# neoMONARCH (NCT02441946)

> A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

No report yet. It can be ordered.

- Drugs tested: abemaciclib plus anastrozole; abemaciclib
- Indication: postmenopausal HR+/HER2- early-stage breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02441946
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Eli Lilly and Company
- Conditions: Breast Cancer; Hormone Receptor Positive Tumor; Early-Stage Breast Carcinoma
- Interventions: Abemaciclib; Loperamide; Anastrozole
- Enrollment: 224
- Primary outcome: Percent Change From Baseline to 2 Weeks in Ki67 Expression

## Indexed commentary on neoMONARCH so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 YouTube videos
- 5 posts on X
- 2 podcast episodes

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=neomonarch-nct02441946

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02441946", "email": "<work email>"}; the inbox owner confirms by the emailed link.